Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 9:44 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 257 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Drugs, Investigational Clear all
Withdrawn Phase 1Phase 2 Interventional

Investigational Drug in Combination With Two Chemotherapy Drugs in Women With Locally Recurrent or Metastatic Breast Cancer

NCT01349088
View directory record Official record
Conditions
Breast Cancer, Metastatic Breast Cancer, Stage IV Breast Cancer
Interventions
Ixabepilone, Capecitabine, Motesanib
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 1, 2025 · Synced Jun 10, 2026, 9:44 PM EDT
Recruiting Phase 1 Interventional

Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors

NCT04222413
View directory record Official record
Conditions
Advanced Solid Tumors, Metastatic Pancreatic Cancer, Pediatric Solid Tumor, Advanced Breast Cancer, Malignant Peripheral Nerve Sheath Tumor, Colorectal Neoplasms
Interventions
Metarrestin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years to 120 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
2
States / cities
Fairway, Kansas • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Jun 10, 2026, 9:44 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Screening of Volunteers for Clinical Trials of Investigational or Licensed Vaccines or Antiviral Products

NCT02242968
View directory record Official record
Conditions
Vaccines, Antiviral Agents, Immunologic Factors, Physiological Effects of Drugs, Anti-Infective Agents
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 120 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Jun 10, 2026, 9:44 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

An Investigational Immuno-Therapy Study of Experimental Medication BMS-986277 Given Alone and in Combination With Nivolumab in Epithelial Cancers

NCT03363776
View directory record Official record
Conditions
Cancer
Interventions
BMS-986277, Nivolumab
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Dec 18, 2020 · Synced Jun 10, 2026, 9:44 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Evaluate Analgesic Efficacy of Fast Release Aspirin

NCT01122602
View directory record Official record
Conditions
Drugs, Investigational
Interventions
Acetylsalicyclic acid (Fast acting Aspirin, BAY1019036), Acetylsalicyclic acid (Aspirin, BAYE4465), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
16 Years to 45 Years
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
2
States / cities
Austin, Texas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 18, 2018 · Synced Jun 10, 2026, 9:44 PM EDT
Recruiting Phase 1Phase 2 Interventional

Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma

NCT06232044
View directory record Official record
Conditions
Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Interventions
Iberdomide, Belantamab Mafodotin, Dexamethasone, Echocardiography, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Bone Marrow Biopsy, Bone Marrow Aspiration, Biospecimen Collection
Drug · Biological · Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
40
States / cities
Ames, Iowa • Boone, Iowa • Fort Dodge, Iowa + 27 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Jun 10, 2026, 9:44 PM EDT
Withdrawn Phase 3 Interventional

An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer

NCT03417037
View directory record Official record
Conditions
Lung Cancer, Non-Small Cell Lung Cancer
Interventions
BMS-986205, Nivolumab, Chemotherapy
Drug · Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
19
States / cities
San Diego, California • Fort Myers, Florida • Jacksonville, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2018 · Synced Jun 10, 2026, 9:44 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Understanding Everyday Stress

NCT05502575
View directory record Official record
Conditions
Stress, Psychological Stress
Interventions
Self-monitoring and personalized stress management, Self-monitoring and general stress management
Behavioral
Lead sponsor
Penn State University
Other
Eligibility
35 Years to 65 Years
Enrollment
213 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 8, 2023 · Synced Jun 10, 2026, 9:44 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Experimental Medication BMS-986235 in Healthy Subjects

NCT03335553
View directory record Official record
Conditions
Mediators of Inflammation
Interventions
BMS-986235, Placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
122 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
2
States / cities
Anaheim, California • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 30, 2022 · Synced Jun 10, 2026, 9:44 PM EDT
Completed Phase 1 Interventional Results available

A Study to Determine the Maximum Tolerated Dose of an Investigational Drug in Subjects With Schizophrenia

NCT03627195
View directory record Official record
Conditions
Schizophrenia
Interventions
DSP-1349M, placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated May 7, 2020 · Synced Jun 10, 2026, 9:44 PM EDT
Completed Phase 3 Interventional

Evaluate Analgesic Efficacy of Fast Release Aspirin

NCT01117636
View directory record Official record
Conditions
Drugs, Investigational
Interventions
Acetylsalicylic acid (Fast release Aspirin, BAY1019036), Acetylsalicylic Acid (Aspirin, BAYE4465), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
16 Years to 45 Years
Enrollment
514 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
2
States / cities
Austin, Texas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 18, 2018 · Synced Jun 10, 2026, 9:44 PM EDT
Completed Not applicable Interventional

Salivary Gland Autotransplantation for Treatment of XRT Induced Xerostomia

NCT04007081
View directory record Official record
Conditions
Xerostomia, Head and Neck Cancer
Interventions
Bone Marrow Aspiration, Ultrasound Imaging of Salivary Glands, Salivary Assay, Quality of Life Instruments
Procedure · Diagnostic Test · Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 89 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 23, 2021 · Synced Jun 10, 2026, 9:44 PM EDT
Terminated Phase 2 Interventional Results available

A Study of Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 With or Without Bacillus Calumette-Guerin (BCG) in BCG Unresponsive Bladder Cancer That Has Not Invaded Into the Muscle Wall of the Bladder

NCT03519256
View directory record Official record
Conditions
Urinary Bladder Neoplasms
Interventions
Nivolumab, BCG, BMS-986205
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
25
States / cities
Los Angeles, California • Riverside, California • San Francisco, California + 21 more
Source: ClinicalTrials.gov public record
Updated May 31, 2023 · Synced Jun 10, 2026, 9:44 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Evaluate Onset of Action of a Fast Release Aspirin

NCT01420094
View directory record Official record
Conditions
Healthy Subjects
Interventions
Acetylsalicyclic acid (Fast release Aspirin, BAY1019036), Acetaminophen (Tylenol extra strength), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
16 Years to 45 Years
Enrollment
510 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 18, 2018 · Synced Jun 10, 2026, 9:44 PM EDT
Completed Phase 2 Interventional Results available

A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Asthma Uncontrolled on Low-Dose ICS Therapy.

NCT00603278
View directory record Official record
Conditions
Asthma
Interventions
GW685698X, placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
622 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
95
States / cities
Phoenix, Arizona • Fort Smith, Arkansas • Little Rock, Arkansas + 82 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2016 · Synced Jun 10, 2026, 9:44 PM EDT
Completed Phase 1 Interventional

DS2330b Alone and With Sevelamer in Patients on Chronic Hemodialysis

NCT03305471
View directory record Official record
Conditions
Hyperphosphatemia
Interventions
DS-2330b PIB, Placebo, Sevelamer, DS-2330b Tablet
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
4
States / cities
Lakewood, Colorado • Orlando, Florida • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2019 · Synced Jun 10, 2026, 9:44 PM EDT
Completed Phase 4 Interventional

Study Of Investigational Regimen Combining FDA Approved HIV Drugs In HIV Subjects Experiencing Early Virologic Failure

NCT00038506
View directory record Official record
Conditions
HIV Infection
Interventions
abacavir/lamivudine/zidovudine, tenofovir
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
27
States / cities
Los Angeles, California • San Rafael, California • Fort Lauderdale, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2015 · Synced Jun 10, 2026, 9:44 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Investigational Study to Determine the Drug Level Profile of BMS-986165 in Healthy Male Volunteers Following Transporter Inhibition.

NCT04086719
View directory record Official record
Conditions
Healthy Male Volunteers
Interventions
BMS-986165, Pyrimethamine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 4, 2020 · Synced Jun 10, 2026, 9:44 PM EDT
Terminated Phase 3 Interventional Results available

A Clinical Trial to Determine the Long-term Safety and Tolerability of an Investigational Drug in People With Major Depressive Episode Associated With Bipolar I Disorder (Bipolar I Depression).

NCT05227209
View directory record Official record
Conditions
Depressive Episodes, Bipolar I Depression
Interventions
SEP-4199 CR
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
25
States / cities
Huntsville, Alabama • Anaheim, California • Imperial, California + 22 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2025 · Synced Jun 10, 2026, 9:44 PM EDT
Completed Phase 1 Interventional Results available

Investigational Agent AG-013736 In Combinations With Standard Of Care Treatments For Patient's With Advanced Solid Tumor

NCT00454649
View directory record Official record
Conditions
Neoplasms
Interventions
Axitinib + Paclitaxel + Carboplatin (Cohort 1), Axitinib + Paclitaxel + Carboplatin (Cohort 2), Axitinib + Paclitaxel + Carboplatin (Cohort 3), Axitinib + Paclitaxel (Cohort 4), Axitinib + Docetaxel + Carboplatin (Cohort 4a), Axitinib + Docetaxel (Cohort 5), Axitinib + Capecitabine (Cohort 6), Axitinib + Capecitabine (Cohort 7), Axitinib + Gemcitabine + Cisplatin (Cohort 8), Axitinib + Pemetrexed + Cisplatin (Cohort 9)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
10
States / cities
Augusta, Georgia • Harvey, Illinois • Tinley Park, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2012 · Synced Jun 10, 2026, 9:44 PM EDT
Completed Phase 2 Interventional Results available

A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver Fibrosis

NCT03486899
View directory record Official record
Conditions
Liver Fibrosis, Nonalcoholic Fatty Liver Disease (NAFLD), Nonalcoholic Steatohepatitis
Interventions
BMS-986036, Placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 75 Years
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
83
States / cities
Madison, Alabama • Chandler, Arizona • Phoenix, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2022 · Synced Jun 10, 2026, 9:44 PM EDT
Completed Phase 1 Interventional Results available

An Investigational Study Drug, Palbociclib (PD-0332991), Is Being Studied In Patients With Mantle Cell Lymphoma. Patients Must Have Received Prior Treatment(s) For Mantle Cell Lymphoma.

NCT00420056
View directory record Official record
Conditions
Lymphoma, Mantle-Cell
Interventions
PD-0332991
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 99 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
6
States / cities
Boston, Massachusetts • New York, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 27, 2015 · Synced Jun 10, 2026, 9:44 PM EDT
Completed Phase 1 Interventional Results available

Study of an Experimental New Drug, PPARγ Agonist Taken by Mouth by Participants With Advanced or Metastatic Cancer

NCT00408434
View directory record Official record
Conditions
Neoplasm
Interventions
CS-7017
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 18, 2020 · Synced Jun 10, 2026, 9:44 PM EDT
Terminated Phase 3 Interventional

Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease

NCT01969136
View directory record Official record
Conditions
Alzheimer's Disease, Dementia
Interventions
Drug: EVP-6124, Placebo
Drug
Lead sponsor
FORUM Pharmaceuticals Inc
Industry
Eligibility
55 Years to 85 Years
Enrollment
403 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
42
States / cities
Tucson, Arizona • Little Rock, Arkansas • Culver City, California + 39 more
Source: ClinicalTrials.gov public record
Updated May 2, 2016 · Synced Jun 10, 2026, 9:44 PM EDT